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Families  who  harbour  deleterious  genetic
alterations in a BRCA gene react differently according
to their situation. Health professionals provide time
and  understanding  within  the  genetic  testing
programme to help individuals consider their options
before proceeding to genetic testing. Once the test
result is confirmed, the affected person may consider
new prevention options to reduce the risk of another
cancer developing. These options may be discussed
with the medical team who are trained in oncology
and genetics. Patients who are gene mutation carriers
and who have developed cancer have a risk to
develop further primaries. Gene carriers who have
developed cancer are managed under different units
with specialists who may not have an in-depth
understanding of the BRCA syndrome. 
The BRCA gene mutation carrier clinic of the Royal
Marsden Hospital/Institute of Cancer Research has
a threefold purpose [1]: 
1. Ongoing support of gene carrier families and
patients. Annual appointments are made for
these patients as well as access to a ”virtual
telephone clinic”. The latter clinic is run by the
nursing team who are trained in oncology and
genetics and who probably know the family well. 
2. Clinical management issues: Discussions related
to further surgical prevention procedures i.e.
mastectomy, prophylactic oophorectomy. All
information is given in the light of the current
research. 
3. The opportunity for family members to participate
in research. Within the Carrier Clinic of the Royal
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This paper highlights the need for carriers to be followed up by health professionals who understand the
complexities of the BRCA syndrome. A BRCA carrier clinic has been established in London and regular follow
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there are several ongoing collaborative studies (as
shown in Figure 1) and patients have the options
to be involved in studies after full informed consent. 
There are nearly 200 patients who have BRCA gene
mutations who are participating in this clinic. For some
people, years later, the effort of attending a clinic
diminishes its attraction, especially if they are unaffected
and have chosen prophylactic surgery as an option.
A ”virtual” clinic has therefore been established as part
of  the  ”carrier  clinic”.  This  means  that  there  is
”telephone availability” for follow up. This telephone
service is managed by the nurses within the unit. It offers
regular follow up support and access for gene carriers
who are worried about their medical health. The service
involves discussions with nurses who are trained in
oncology and genetics and who have experience in
working with BRCA gene mutation carriers. 
Families with mutations in the BRCA genes know that
they can contact the ”virtual clinic” at any time for support
or advice. Medical matters are acted on immediately via
a link with the Consultant in charge. If a patient is already
under another unit/hospital, then contact is made with
the appropriate medical person accompanied by a follow
up  letter  and  appropriate  investigations.  In  some
instances, preliminary investigations such as blood tests
are arranged before referral thereby providing maximum
information for the specialist. 
This following case is illustrative of the virtual clinic
and the referral process. 
T Th he e   C Ca as se e   o of f   M Mr rs s   X X   
Mrs X is a known BRCA1 mutation carrier. She was
keen to be tested as so many of her female relations had
died prematurely from cancer. Information from another
centre provided her with the knowledge that there was
a deleterious mutation present in the BRCA1 gene in her
family. At the age of 33 she underwent predictive genetic
testing and had several sessions with the Clinical Nurse
Specialist and the medical team before deciding to
proceed. The testing showed that she carried the
pathogenic mutation identified in her family. After serious
consideration, she decided to undergo prophylactic
ovarian surgery. This she hoped would reduce her life
time risk of ovarian cancer of 50% by about 96% and
reduce her risk of developing breast cancer by 50% [2].
After serious consideration following several counselling
sessions, she was referred to the gynaecologist for
discussions on risk reducing surgery. She had a medical
history of endometriosis and decided along with her
gynaecologist to have a total hysterectomy as she was
troubled by menstrual problems. Furthermore, she had
two children and was adamant that she did not wish to
have any more children. This operation was successful.
She was followed up in the breast unit for annual
screening. As part of the ”virtual clinic” for gene carriers,
ongoing support was available for this young lady who
had a limited family support structure. On one of the
regular follow up calls, she sounded depressed and was
therefore invited in to the nurse who led follow up clinic.
During this session, she informed the nurse that she was
feeling tired and ”not herself”. This young lady was
known well to the nurse through the predictive genetic
testing programme. The nurse was concerned that there
maybe  something  medical  that  needed  serious
consideration. Furthermore, as part of the BRCA clinic
protocol, patients who have undergone prophylactic
oophorectomy  are  offered  a CA125  test  with  the
knowledge that this test’s predictive value in this situation
is uncertain. In this particular case, the Consultant and
the nurse were in discussion about the management of
this young lady and a CA125 test was arranged along
with a few other blood tests.
The CA125 result was elevated (130). A transvaginal
ultrasound scan and another CA125 test was arranged
along with an appointment to the gynaecology clinic.
Unfortunately, this young woman was found to have an
early  stage  primary  peritoneal  cancer.  She  has
undergone intensive chemotherapy and is currently
being followed up in the onco-gynaecology unit for her
cancer care. As well, there is ongoing genetic support
for this young woman when needed. She continues to
be followed up in the breast unit for breast screening. 
The ongoing follow up for this young woman as
part of the Carrier Clinic has shown the benefits of this
follow up service both from a medical management
perspective and a psychological support service. It is
essential that there are professionals who understand
the BRCA syndrome in the fullest sense, including both
genetic and oncological perspectives and the possible
associated further cancer risks. As it is such a specialist
area of knowledge, the patient is well served with
qualified  professionals  who  will  liaise  with  the
appropriate health professionals. 
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D DU UC CT TA AL L   L LA AV VA AG GE E   S ST TU UD DY Y
Ductal Lavage in BRCA1and BRCA2mutation carriers and non-carriers
W Wh ha at t   i is s   t th he e   s st tu ud dy y   f fo or r? ?   
We are interested in looking at the fluid within the ducts of the breast as it is made by and bathes the cells that 
can become cancerous. It is possible that by analysing this fluid for the presence of cells and chemical markers
we could identify early cases of breast cancer or use the information to give abetter estimate breast cancer risk. 
W Wh ho o   i is s   e el li ig gi ib bl le e? ?   
Women with aknown alteration in aBRCA1 or BRCA2 gene and women who have tested  
negative for an alteration in either of these 2genes which is known to be present
in the family. Women with at least one breast unaffected by cancer. 
Exclusions include pregnancy and breast-feeding within the last 12 months. 
W Wh ha at t   d do oe es s   i it t   i in nv vo ol lv ve e? ?   
Local anaesthetic cream is used to numb the nipple area. An extremely fine, 
flexible tube is passed into the nipple ducts, coated in anaesthetic jelly, 
and afew millilitres of adilute salt solution is introduced into the duct to wash it out. 
N NI IP PP PL LE E   A AS SP PI IR RA AT TI IO ON N   S ST TU UD DY Y
Nipple aspiration in women – BRCA1, BRCA2 and p53 mutation carriers. 
W Wh ha at t   i is s   t th he e   s st tu ud dy y   f fo or r? ?   
We are interested in looking at the fluid within the ducts of the breast as it is made by and bathes 
the cells that can become cancerous. It is possible that by analysing this fluid for the presence 
of cells and chemical markers we could identify early cases of breast cancer 
or use the information to give abetter estimate breast cancer risk. 
W Wh ho o   i is s   e el li ig gi ib bl le e? ?   
Women with aknown alteration in aBRCA 1, BRCA 2or p53 gene under the age of 65. 
Women with at least one breast unaffected by cancer.
Exclusions include pregnancy and breast-feeding within the last 12 months. 
W Wh ha at t   d do oe es s   i it t   i in nv vo ol lv ve e? ?   
A sample of fluid taken from the nipple using aspecial pump, similar to that used for expressing milk during
breast-feeding. The breast is warmed and gently massaged to move duct fluid towards the nipple. The
procedure does not use aneedle and has been well tolerated by women previously. 
T TH HE E   E EM MB BR RA AC CE E   S ST TU UD DY Y
Lifestyle study of BRCA1 and BRCA2 gene alteration carriers
W Wh ha at t   i is s   t th he e   s st tu ud dy y   f fo or r? ?   
We know that some BRCA1 and BRCA2 gene alteration 
carriers get breast cancer, but we do not know what 
other genetic or lifestyle factors may be important. 
This study is trying to identify these other risk factors. 
W Wh ho o   i is s   e el li ig gi ib bl le e? ?   
Members of families where aBRCA1 or BRCA2 gene alteration 
has been identified. Anyone can take part whether they have 
the gene or not, and even if they have not been tested. 
W Wh ha at t   d do oe es s   i it t   i in nv vo ol lv ve e? ?   
A simple questionnaire about background, medical 
and family history, 
and an optional blood test (not a”gene test”).
I IM MP PA AC CT T   S ST TU UD DY Y
This study is an international targeted prostate screening study 
of male BRCA1 and BRCA2 mutation carriers. 
W Wh ha at t   i is s   t th he e   s st tu ud dy y   f fo or r? ?   
Men who carry alterations in these genes are known to be at 
ahigher risk of prostate cancer. This study aims to look 
at substances which may be markers for prostate cancer 
in the blood and urine of these men. 
W Wh ho o   i is s   e el li ig gi ib bl le e? ?   
Men aged 40-69 who have aknown alteration in either the BRCA1 
or BRCA2 gene with no history of prostate cancer. We are also looking 
at their male relatives who do not carry this gene to compare the results. 
W Wh ha at t   d do oe es s   i it t   i in nv vo ol lv ve e? ?   
A blood and urine sample will be taken annually for atotal of 5years. 
People are also asked to complete ashort personal history questionnaire.
E EF FF FE EC CT TS S   O OF F   R RA AD DI IA AT TI IO ON N   S ST TU UD DY Y
Study to assess the effects of radiation in BRCA1 
and BRCA2 carriers versus non-carriers
W Wh ha at t   i is s   t th he e   s st tu ud dy y   f fo or r? ?   
Cancer is often treated with radiation (i.e. radiotherapy),
or screening for it uses radiation. We are trying 
to determine whether gene alteration carriers are 
any more or less sensitive to radiation than those 
who do not carry an alteration. At present the answer 
to this question is unknown, and this study will help 
us to design future treatments. 
W Wh ho o   i is s   e el li ig gi ib bl le e? ?   
Any woman who has aknown alteration 
in aBRCA1 or BRCA2 gene. 
W Wh ha at t   d do oe es s   i it t   i in nv vo ol lv ve e? ?   
A one-off blood sample, and some people may be asked 
to give asmall skin biopsy, usually from the buttock. 
These samples are used to study how blood 
and skin cells behave after irradiation. 
O OU UT TC CO OM ME E   O OF F   B BR RE EA AS ST T   C CA AN NC CE ER R   T TR RE EA AT TM ME EN NT T   S ST TU UD DY Y
Study to assess the effects of radiotherapy and chemotherapy in treatment for breast cancer 
W Wh ha at t   i is s   t th he e   s st tu ud dy y   f fo or r? ?   
We are trying to find out which treatment for beast cancer gives the best results (in tumour control and
cosmetic effect) in women who have had cancer due to an alteration in aBRCA1 or BRCA2 gene. We do
not know whether women who carry an alteration have any significant differences in their responses to
radiotherapy and chemotherapy compared to the general population of women with breast cancer. 
W Wh ho o   i is s   e el li ig gi ib bl le e? ?   
Women who have had chemotherapy and/or radiotherapy as part of breast cancer treatment. 
Both women with an alteration in aBRCA1 or BRCA2 gene, and women in the general population
with breast cancer are eligible. 
W Wh ha at t   d do oe es s   i it t   i in nv vo ol lv ve e? ?   
A one-off visit to the hospital. Questions are asked about what treatment was undergone, and where and
when it was carried out. Photographs are taken of the breasts to evaluate the cosmetic outcome of
treatment, and some people may be asked to have asmall skin biopsy. 
Data about any treatment and subsequent follow-up are taken from the hospital notes. 
We are also interested in finding out if there are any differences in the facial and general features of
women who carry aBRCA1 or BRCA2 gene alteration. If people are willing, we are taking photographs of
the head and shoulders. This information may help us in future assessments of the likelihood of individuals
being alteration carriers. 
A Allll  p ph ho ot to og gr ra ap ph hs s  t ta ak ke en n  iin n  t th hiis s  s st tu ud dy y  w wiillll  b be e  u us se ed d  ffo or r  s st tu ud dy y  p pu ur rp po os se es s  o on nlly y,,  
a an nd d  w wiillll  n no ot t  b be e  u us se ed d  ffo or r  t te ea ac ch hiin ng g  o or r  iin n  p pu ub blliic ca at tiio on ns s  w wiit th ho ou ut t  a an n  iin nd diiv viid du ua all’’s s  w wr riit tt te en n  c co on ns se en nt t..  
T TH HE E   P PR RO OS SE E   S ST TU UD DY Y   
Preventative surgery in carriers of BRCA1 and BRCA2 gene alterations 
(PROSE stands for Prevention and Observation of Surgical Endpoints) 
W Wh ha at t   i is s   t th he e   s st tu ud dy y   f fo or r? ?   
We are trying to find out the long-term effects of preventative surgery in BRCA1 and BRCA2 gene alteration carriers. 
Some women choose to have their breasts and/or ovaries removed to prevent getting cancer. We want to find out exactly 
how much this kind of surgery reduces the incidence of cancer, and how lifestyle factors may be involved. 
W Wh ho o   i is s   e el li ig gi ib bl le e? ?   
We want to study both women who have had preventative surgery to the breasts and/or ovaries, and those who have not. 
The eligibility criteria for this study are alittle complicated, but most women with aknown BRCA1 or BRCA2 gene will be eligible. 
W Wh ha at t   d do oe es s   i it t   i in nv vo ol lv ve e? ?   
Data about any treatment and subsequent follow-up are taken from the hospital notes. People are asked to fill in asimple questionnaire about
background, medical and family history. This questionnaire is very similar to the one used in the Embrace study. If aperson consents to take part in
the PROSE study and has already filled in the Embrace questionnaire, there is no need to fill this in again as we can share the data. 
P PR RO OP PH HY YL LA AC CT TI IC C   M MA AS ST TE EC CT TO OM MY Y   S ST TU UD DY Y
Evaluation of the effectiveness of prophylactic mastectomy 
(i.e. preventative removal of the breasts) 
W Wh ha at t   i is s   t th he e   s st tu ud dy y   f fo or r? ?   
We are trying to find out the long-term effects of preventative 
breast surgery. Some women choose to have their breasts 
removed to prevent cancer. We want to find out exactly 
how much this kind of surgery reduces the incidence of cancer 
in women, and how it affects their general physical health 
and psychological well being over time. 
W Wh ho o   i is s   e el li ig gi ib bl le e? ?   
This is a”prospective” study. Women who are going 
to have preventative surgery to the breasts are eligible. 
W Wh ha at t   d do oe es s   i it t   i in nv vo ol lv ve e? ?   
Data about any treatment and subsequent follow-up are taken
from the hospital notes. Aquestionnaire is filled in before 
surgery, and then at 3months, 1, 5and 10 years 
after the surgery. It asks about general health, 
cancer worry, body image and relationships. 
RESEARCH PROJECTS INVOLVING BRCA1 
AND BRCA2 ALTERATION CARRIERS
AT THE ROYAL MARSDEN HOSPITAL